1
Return

Hyperglycemia during ICI Therapy: etiology, risk factors, and survival outcome

delete2026-08-13
delete0
PRE
AI
M
Min Shen
X
Xinpan Wang
T
Tianyu Gao
Y
Yin Jiang
W
Wenxuan Bian
X
Xuqin Zheng *
T
Tao Yang *
Y
Yun Shi *
DOI:10.1007/s40618-026-03018-8delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
The spectrum of hyperglycemia and its association with overall survival (OS) in patients receiving immune checkpoint inhibitors (ICIs) are not characterized. We retrospectively analyzed 4,119 patients who had received ≥ 1 dose of PD-1 or PD-L1 inhibitors during a period from July 1st 2018 to March 1st 2022 at the First Affiliated Hospital with Nanjing Medical University. We assessed the characteristics of patients with hyperglycemic during ICIs. Multivariable Cox regression models and Propensity score matching (PSM) were utilized to analyze the risk of hyperglycemic and OS differences. After excluded 1,283 patients without follow-up fasting blood glucose (FBG) data, 2,836 patients were included. 24.33% (690/2,836) patients experienced hyperglycemia during ICIs. In patients with new-onset hyperglycemia (n = 410), the main etiologies were steroid‑related (31.22%), new‑onset T2DM (27.32%), ICI‑T1DM (4.39%), and ICI‑pancreatitis (0.73%). Independent risk factors included pre‑existing diabetes (OR: 6.970, 95% CI: 4.841, 10.036), digestive system tumors (OR:1.862, 95% CI: 1.382, 2.509), supraphysiologic steroid use (OR:2.009, 95% CI: 1.494, 2.700), and baseline FBG (OR: 2.824, 95% CI: 2.485, 3.209). A prediction model incorporating these factors showed good discrimination (AUC 0.84, 95% CI 0.82–0.86). Multivariable and PSM analyses revealed no statistically significant association between glycemic status and OS, nor did ICI‑T1DM independently affect survival. A range of pathologies can contribute to elevated glucose, thus careful clinical assessment of those with hyperglycemia is required.
Keywords:
Immune checkpoint inhibitors
Hyperglycemic
Real-world cohort
Overall survival

Journal

J
Journal of Endocrinological Investigation
IF:
3.5
Papers:
6.0K
Citations:
8.9K

Organization

D
Department of Endocrinology and Metabolism
Scholars:
590
Papers: 201
Citations: 0
Cited Papers

Cited Papers

Citing Papers

Citing Papers